1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: generic
Jacobson Pharma Corporation Limited

Jacobson Pharma Corporation Limited

HHKEX:2633
0.93
HKD
0.00
(0.00%)
2.46BMarket Cap
Nov 20Next Earn
Jacobson Pharma Corporation Limited
HKEX:2633
(Hong Kong Exchange)

Recent

price

0.93

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
HKD
0.53
0.54
0.83
0.8
0.85
0.77
0.79
0.75
0.83
0.66
0.76
0.79
0.79
- -
Revenue per Share
0.1
0.06
0.11
0.11
0.11
0.13
0.11
0.09
0.09
0.13
0.14
0.15
0.15
- -
Basic EPS, GAAP
-0.03
-0.1
0.07
0.05
0.09
0.18
0.14
0.18
0.18
0.3
0.18
0.14
0.1
- -
Free Cash Flow per Basic Share
- -
0.01
- -
0.15
0.02
0.05
0.05
0.03
0.03
0.05
0.05
0.03
0.16
- -
Dividend per Share
0.5
0.55
0.52
0.96
1.09
1.31
1.32
1.25
1.3
1.43
1.2
1.23
1.16
1.16
Book Value per Share
0.29
0.31
0.27
0.38
0.49
0.78
0.64
0.55
0.62
0.74
0.98
1.02
0.94
0.94
Tangible Book Value per Share
1,750
1,750
1,309
1,574
1,816
1,931
1,983
1,916
1,916
1,911
1,920
1,986
1,998
1,998
Basic Weighted Avg Shares
926
948
1,084
1,256
1,549
1,478
1,571
1,446
1,596
1,268
1,468
1,577
1,569
- -
Sales/Revenue/Turnover
17.03
14.02
17.26
17.8
17.98
22.56
18.33
16.22
13.81
21.31
19.63
23.4
22.79
- -
Operating Margin (%)
44
53
70
82
112
116
171
192
193
184
142
144
154
- -
Depreciation Expense
172
102
146
179
202
251
216
174
178
251
267
301
302
- -
Net Income, GAAP
14.86
16.28
16.58
18.07
18.44
17.96
17.47
15.53
18.89
17.17
17.45
19.48
16.82
- -
Effective Tax Rate (%)
18.61
10.75
13.43
14.28
13.06
16.95
13.72
12.01
11.14
19.8
18.19
19.08
19.22
- -
Profit Margin (%)
-44
-256
-317
-225
-220
190
443
287
352
1,101
592
485
269
269
Working Capital
7
1
1
- -
1
372
1,062
927
764
1,255
610
512
406
406
LT Debt
917
1,007
956
1,772
2,008
2,687
2,606
2,860
2,958
3,257
2,396
2,477
2,340
2,340
Total Equity
- -
8.55
10.69
9.33
7.96
8.26
6.36
4.93
4.75
5.6
6.84
10.36
9.85
- -
Return on Invested Capital (%)
- -
6.8
9.76
9.2
7.81
8.08
6.26
4.26
4.25
5.85
7.7
10.45
10.06
- -
Return on Capital (%)
- -
11.11
15.62
13.5
10.86
10.84
8.32
7.05
7.28
9.6
10.45
12.47
12.65
- -
Return on Common Equity (%)

Capital Structure

HKD

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
ST Debt
261
422
505
LT Borrowings
477
445
380
LT Finance Leases
36
38
27
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,994
2,000
2,000
Market Capitalization
2,353
2,920
2,460

Working Capital

HKD

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
Total Current Assets
1,038
967
986
Cash, Cash Equivalents & STI
509
395
370
Accounts Receivable, Net
145
164
176
Inventories
333
348
372
Total Current Liabilities
553
686
717
Payables & Accruals
- -
- -
- -
ST Debt
261
422
505
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.41%
-3.01%
-5.54%
Free Cash Flow
20.43%
-5.09%
-30.96%
Net Income, GAAP
8.93%
12.57%
0.26%
Sales/Revenue/Turnover
4.55%
2.51%
-0.47%
Total Cash Common Dividend
1,366.71%
93.06%
428.75%

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1,468
2025
- -
- -
1,577
2026
- -
- -
1,569

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.14
2025
- -
- -
0.15
2026
- -
- -
0.15

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.05
2025
- -
- -
0.03
2026
- -
- -
0.16
Similar Companies
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Teva Pharmaceutical Industries Limited (TASE:TEVA)
Jagsonpal Pharmaceuticals Ltd. (NSE:JAGSNPHARM)
Zim Laboratories Ltd. (NSE:ZIMLAB)
Paradigm Biopharmaceuticals Ltd. (ASX:PAR)
Neuren Pharmaceuticals Limited (ASX:NEU)
Business
Jacobson Pharma Corporation Limited is a prominent pharmaceutical enterprise, vertically integrated for the research, development, manufacturing, distribution, and commercialization of essential and specialty medicines. The company serves healthcare professionals and patients across Hong Kong, Mainland China, Macau, Singapore, and other international markets. Its extensive portfolio of generic drugs addresses a wide array of therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, respiratory, musculoskeletal, genito-urinary, endocrine and metabolic, dermatological, anti-allergics, and anti-infective conditions. Notable developments include the broadening market reach for Arsenic Trioxide Oral Solution, co-developed with The University of Hong Kong for acute promyelocytic leukemia, expanding into Southeast Asia. While historically involved in branded healthcare products and proprietary Chinese medicines, the branded healthcare segment's operations were classified as discontinued for the fiscal year ended March 31, 2024. The company continues to strengthen its core through a robust R&D pipeline, comprising 219 products as of March 2025, and strategic in-licensing agreements for 20 high-performing specialty drugs across immunology, oncology, cardiology, neurology, and rare diseases. Jacobson Pharma distributes its pharmaceutical offerings to public and private healthcare sectors, encompassing hospitals, clinics, licensed pharmacies, private medical practitioners, and various retail and trading partners. The firm reported total revenue of approximately HK$1,576.9 million for the year ended March 31, 2025, with profit from continuing operations increasing by 43.1% to HK$300.8 million, reflecting sustained growth and operational efficiency. In February 2025, the company launched supply chain liaison services for Axicabtagene Ciloleucel, a CAR-T therapy, in partnership with Shanghai Fosun Pharmaceutical. A new smart pharmaceutical manufacturing facility is also under development at Tai Po InnoPark, with trial production anticipated in late 2026. Incorporated in 2016, the company maintains its headquarters in Kwun Tong, Hong Kong, and operates as a subsidiary of Kingshill Development Limited.